Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Stockholders Equity (Deficit)

v3.20.1
Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Series B Preferred Stock [Member]
Total
Balance at Dec. 31, 2018 $ 15,000 $ 230,754,000 $ (219,461,000) $ (2,909,000) $ 5,760,000 $ (14,159,000)
Balance (in shares) at Dec. 31, 2018 15,482,083       9,161  
Stock-based compensation   64,000       64,000
Series A Preferred Stock Dividends     (61,000)     (61,000)
Issuance of SYN Biomics Stock   (36,000)   53,000   17,000
Conversion of Series B Preferred Stock to Common $ 1,000 1,035,000 (398,000)   $ (638,000)  
Conversion of Series B Preferred Stock to Common (in shares) 900,869       (1,036)  
Net loss     (3,512,000)     (3,512,000)
Non-controlling interest       (16,000)   (16,000)
Balance at Mar. 31, 2019 $ 16,000 231,817,000 (223,432,000) (2,872,000) $ 5,122,000 10,651,000
Balance (in shares) at Mar. 31, 2019 16,382,952       8,125  
Balance at Dec. 31, 2018 $ 15,000 230,754,000 (219,461,000) (2,909,000) $ 5,760,000 (14,159,000)
Balance (in shares) at Dec. 31, 2018 15,482,083       9,161  
Balance at Dec. 31, 2019 $ 17,000 232,580,000 (235,537,000) (2,878,000) $ 4,761,000 (1,057,000)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638  
Stock-based compensation $ 0 83,000 0 0 $ 0 83,000
Series A Preferred Stock Dividends 0 0 (62,000) 0 0 (62,000)
Issuance of SYN Biomics Stock 0 0 0 26,000 0 26,000
Conversion of Series B Preferred Stock to Common $ 1,000 1,072,000 (404,000) 0 $ (669,000) 0
Conversion of Series B Preferred Stock to Common (in shares) 933,045       (1,073)  
Net loss $ 0 0 (2,964,000) 0 $ 0 (2,964,000)
Non-controlling interest 0 0 0 (26,000) 0 (26,000)
Balance at Mar. 31, 2020 $ 18,000 $ 233,735,000 $ (238,967,000) $ (2,878,000) $ 4,092,000 $ (4,000,000)
Balance (in shares) at Mar. 31, 2020 17,739,475       6,565